Item 9 Labs

INLB · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About INLB

Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor. The company is headquartered in Phoenix, Arizona and currently employs 97 full-time employees. The company went IPO on 2011-11-03. The firm is a vertically integrated cannabis operator and dispensary franchisor delivering products from large-scale cultivation and production facilities in the U.S. The firm operates in two segments: Cultivation, which includes the cultivation, production, and sale of cannabis and cannabis-derived products and technologies distributed through licensed medical and adult-use dispensaries under its Item 9 Labs brand in Arizona, and Franchising, which involves the sales of franchises to dispensaries. The company offers a dispensary franchise model through the national Unity Rd. retail brand. The firm offers approximately 75 active cannabis strains, more than 150 differentiated cannabis vaporizer (vape) products, concentrates, and Orion vape technologies. Its product lines include Item 9 Labs Flower, Item 9 Labs Concentrates, and Orion 710.

Employees
97
Headquarters
Phoenix, Arizona
Listed
Nov 3, 2011
Sector
Health Care
Industry
Pharmaceuticals

INLB key statistics

Market cap
702
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
29.07K
Volume
350
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0001
52 Week low
$0.00

Item 9 Labs (INLB) at a glance

Item 9 Labs (INLB) last traded at $0.00, with a market cap of 702 and a price-to-earnings ratio of 0.00.

Volume so far is 350 shares, below the average of 29.07K shares a day.

Over the past year Item 9 Labs has ranged from $0.00 to $0.0001, and now sits 0% of the way up that range.

Item 9 Labs met or beat analyst EPS estimates in 1 of the last 6 quarters. In Q4 FY22 it reported -$0.20 per share against an estimate of -$0.0408.

INLB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 6 quarters, by 2.0% on average.

  1. Q3 FY21: reported -$0.01 per share against an estimate of $0.00
  2. Q4 FY21: reported -$0.09 per share against an estimate of $0.00
  3. Q1 FY22: reported -$0.04 per share against an estimate of -$0.0408
  4. Q2 FY22: reported -$0.04 per share against an estimate of -$0.0306
  5. Q3 FY22: reported -$0.06 per share against an estimate of -$0.0306
  6. Q4 FY22: reported -$0.20 per share against an estimate of -$0.0408

Similar companies

Companies in the same industry as Item 9 Labs

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.